BIOCEV is a joint project of six institutes of the Academy of Sciences of the Czech Republic (Institute of Molecular Genetics, Institute of Biotechnology, Institute of Microbiology, Institute of Physiology, Institute of Experimental Medicine, and Institute of Macromolecular Chemistry) and two faculties of Charles University in Prague (Faculty of Science and 1st Faculty of Medicine). The project’s goal is to establish European Centre of Excellence in biomedicine and biotechnology.
In January 2016, the Institute of Biotechnology CAS (IBT) moved to a BIOCEV centre and is involved in two of the five research programmes. IBT wants to take full advantage of this chance to produce cutting-edge scientific results that will be transferred into clinical practice.
BIOCEV: Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University in Vestec
BIOCEV builds upon three pillars of the knowledge triangle: teaching and education, research and development, and transfer of research results into practice.
The uniqness of the project lies in well-balanced activities and goals set within the three pillars of the knowledge triangle, in BIOCEV supported by modern infrastructure and novel approaches to conducting research, which are based on the experience of top-quality world research institutes.
Aim: detailed study of cellular mechanisms at the molecular level, research and development of novel therapeutic strategies, early diagnostics, biologically active agents including chemotherapeutics, protein engineering and other technologies with impact on the quality of life, development of knowledge economy and competitive capacity of the Czech Republic.
Five programme areas: Functional Genomics, Cell Biology and Virology, Structural Biology and Protein Engineering, Biomaterials and Tissue Culture Engineering, and Development of Therapeutic and Diagnostic Strategies
Unique top-quality technology in central laboratories
BIOCEV: intro - cochlea and heart.
The idea to establish the new research centre BIOCEV arose in early 2006. At that time the Czech Republic was missing a modern research centre specialized in two prospective domains – biotechnology and biomedicine. As a solution to this situation, the Project BIOCEV came into existence with the planned financial support from the European Structural Funds, namely the Operational programme Research and Development for Innovations.